Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Current Liabilities: 2022-2025

Historic Total Current Liabilities for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $360.3 million.

  • Axsome Therapeutics' Total Current Liabilities rose 83.65% to $360.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.3 million, marking a year-over-year increase of 83.65%. This contributed to the annual value of $230.1 million for FY2024, which is 65.72% up from last year.
  • Per Axsome Therapeutics' latest filing, its Total Current Liabilities stood at $360.3 million for Q3 2025, which was up 5.32% from $342.1 million recorded in Q2 2025.
  • Axsome Therapeutics' Total Current Liabilities' 5-year high stood at $360.3 million during Q3 2025, with a 5-year trough of $24.5 million in Q1 2022.
  • Its 3-year average for Total Current Liabilities is $197.5 million, with a median of $186.6 million in 2024.
  • Data for Axsome Therapeutics' Total Current Liabilities shows a peak YoY spiked of 309.99% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Total Current Liabilities stood at $96.6 million in 2022, then soared by 43.80% to $138.9 million in 2023, then surged by 65.72% to $230.1 million in 2024, then soared by 83.65% to $360.3 million in 2025.
  • Its Total Current Liabilities stands at $360.3 million for Q3 2025, versus $342.1 million for Q2 2025 and $243.9 million for Q1 2025.